Profound Medical Shares Rise 5% in 1 Day Since Partnering with Telix Pharmaceuticals

Key highlights

• Partnership integrates Telix’s Gozellix and Illuccix imaging technologies with Profound’s TULSA-PRO platform
• Collaboration aims to expand specialist awareness via major scientific meetings and key opinion leader programs
• Profound is developing PSMA-PET–MR image-fusion software to enhance clinical stratification for higher-risk patients
• Management recently issued preliminary Q3 2026 revenue guidance between $9.8 million and $10.0 million
• Company maintains a qualified sales pipeline estimated at approximately $70 million as of August 2026

What Is the Partnership?

Profound Medical has established a formal framework with Telix Pharmaceuticals to co-educate the medical community on the synergy between molecular imaging and incisionless therapy. The agreement targets urologists, radiologists, and nuclear medicine physicians, providing them with clinical case studies and best-practice materials that highlight how Telix’s PSMA-PET tracers, Illuccix and Gozellix, complement the TULSA-PRO platform. This initiative is designed to standardize PSMA-informed treatment pathways, ensuring that physicians can better utilize advanced imaging to guide MRI-led robotic ablation. The partnership includes joint participation in global medical summits and the development of educational webinars to drive platform adoption.

Partner Profile

Telix Pharmaceuticals Limited is a commercial-stage global radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Targeted Radiation. Listed on both the ASX and NASDAQ, Telix specializes in precision medicine, particularly within the oncology sector. Their PSMA-PET imaging technologies are recognized for providing high-resolution diagnostic data, which is critical for identifying the extent of prostate cancer. By partnering with a major radiopharmaceutical player, Profound gains access to an established international network of urology and imaging centers, leveraging Telix’s expertise in molecular targeting to validate the clinical utility of the TULSA procedure in more complex cancer cases.

What It Unlocks

• Facilitates the identification of distant metastases, helping physicians determine if patients with higher-risk disease are suitable for TULSA-PRO
• Drives the development of PSMA-PET–MR image-fusion capabilities to create more precise, AI-powered treatment plans
• Increases institutional return on investment by integrating Telix’s diagnostic tools within existing TULSA-PRO treatment centers
• Broadens the addressable patient population by enabling more granular patient stratification through advanced molecular data

Financial Context

This partnership comes as Profound Medical continues to scale its commercial footprint, evidenced by a recent preliminary Q3 2026 revenue guidance of $9.8 million to $10.0 million, representing significant growth. The company previously reiterated a full-year 2026 revenue target of approximately $25.0 million, supported by a qualified sales pipeline of $70 million. Historically, the company has utilized strategic collaborations to expand, including a co-sales agreement with Siemens Healthineers and distribution deals in Asia and the Middle East. The integration of PSMA-PET technology is expected to strengthen the clinical value proposition of the TULSA-PRO platform ahead of the full Q3 financial report on November 5, 2026.

Up 2.2% since our story on 9 Oct: $6.86 when we broke it → $7.01 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$5.81
15 Sep	$5.68
16 Sep	$5.83
17 Sep	$5.89
18 Sep	$5.86
21 Sep	$6.10
22 Sep	$5.89
23 Sep	$5.74
24 Sep	$5.60
25 Sep	$5.76
28 Sep	$5.92
29 Sep	$5.72
30 Sep	$5.80
1 Oct	$5.85
2 Oct	$5.84
5 Oct	$6.03
6 Oct	$6.08
7 Oct	$5.68
8 Oct	$6.91
9 Oct	$6.90
12 Oct	$7.25
13 Oct	$7.01

Management commentary

“By bringing together advanced molecular imaging and incisionless, MRI-guided therapy, we see an opportunity to support broader market development, enhance clinical education and increase awareness of the complementary value of our respective technologies.”

“Through this collaboration with Profound, we aim to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy and support more personalized care for patients.”

Profound Medical Corp. · financial snapshot

Share price	$6.86
Market cap	$251M
Revenue (annual)	$16M
1-month price change	+0.88%
Sector	HealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.